Stock Expert AI
Equity research screen

Merck & Co. (MRK) Stock Forecast 2026

This page provides a forecast for Merck & Co. (MRK) extending to 2026. It consolidates available analyst estimates and offers context on MRK's sector. The information serves as a resource for evaluating potential future performance. Note that forecasts are inherently uncertain and should not be the sole basis for investment decisions. This research note is strictly informational and is not investment advice.

Quick Answer This page provides a stock forecast for Merck & Co. (MRK) extending to 2026. The forecast is assembled by aggregating available analyst estimates and considering the company's position within the Healthcare sector. Forecasts are derived from analyst estimates and should be viewed as informational rather than definitive predictions.
Stocks12Screens50Average score95.17Ranked as of2026-09-11
Data sources: Financial Modeling Prep | Yahoo Finance | SEC Filings 21,000+ US companies analyzed

Merck & Co. (MRK) Forecast and Sector Context

This forecast assesses the potential trajectory of Merck & Co. (MRK) within the Healthcare sector through 2026. The analysis incorporates available projections to provide a forward-looking perspective on the company. This information is intended to support informed decision-making but should not replace individual due diligence.

Names rising to the top of the screen

The strongest names remain easy to scan without losing the valuation context behind the ranking.

Names rising to the top of the screen — the subject company first, then its sector leaders by MoonshotScore; prices refresh on page view.
# Ticker Company AI Score Price Change Market Cap P/E
1 MRK Merck & Co., Inc. 74 $144.71 -1.91% $357.4B 114.8
2 INCY Incyte Corporation 98 $123.28 -2.17% $25.0B 15.2
3 KRYS Krystal Biotech, Inc. 98 $345.55 -0.73% $10.2B 41.8
4 EXEL Exelixis, Inc. 98 $56.20 -2.14% $14.4B 17.5
5 ETON Eton Pharmaceuticals, Inc. 97 $57.15 -1.26% $1.6B 124.5
6 HRMY Harmony Biosciences Holdings, Inc. 97 $41.10 -1.25% $2.4B 13.1
7 NHC National HealthCare Corporation 97 $224.92 -1.02% $2.2B
8 INSP Inspire Medical Systems, Inc. 97 $73.00 +7.16% $2.0B 14.6
9 ARGX argenx SE 97 $984.04 -1.82% $61.2B 36.0
10 UTHR United Therapeutics Corporation 97 $503.86 -0.58% $21.4B 16.7
11 ATRC AtriCure, Inc. 96 $53.83 +1.64% $2.7B 249.6
12 GRDN Guardian Pharmacy Services, Inc. 96 $43.66 -0.39% $2.8B 41.7

Where valuation pressure is clustering

Healthcare100%

Key Considerations for Merck & Co. (MRK)

When evaluating forecasts, consider prevailing economic conditions, industry trends, and company-specific developments. Review MRK's performance, financial health, and strategic initiatives. Note that forecasts are inherently uncertain and represent potential future outcomes, not guarantees.
“MoonshotScore rates a US-listed stock 0 to 100 — higher means stronger numbers. Most carry an older nine-factor score; the rest use five sector-relative pillars, re-ranked daily — common stocks and ADRs only. Funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
— Stock Expert AI published methodology (how MoonshotScore works)

Questions worth resolving before acting on the screen

How accurate are stock forecasts?

Stock forecasts are estimates and not guarantees of future performance. Numerous factors can influence actual results.

What factors can affect MRK's stock price?

Company performance, industry trends, and broader economic conditions can impact MRK's stock price.

Where can I find more information on MRK?

Refer to Merck & Co.'s investor relations page and reputable financial news sources for detailed information.

Explore More Research

Stock Expert AI provides data and analysis tools for educational purposes. This is not financial advice. Past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. Data sources: Financial Modeling Prep, Yahoo Finance.